BIIB Stock Forecast 2025-2026
Distance to BIIB Price Targets
BIIB Price Momentum
10 Quality Stocks Worth Considering Now
Researching Biogen (BIIB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BIIB and similar high-potential opportunities.
Latest BIIB Stock Price Targets & Analyst Predictions
Based on our analysis of 44 Wall Street analysts, BIIB has a neutral consensus with a median price target of $185.00 (ranging from $121.00 to $342.00). The overall analyst rating is Buy (7.6/10). Currently trading at $118.61, the median forecast implies a 56.0% upside. This outlook is supported by 16 Buy, 19 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Morten Herholdt at HSBC, projecting a 188.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BIIB Analyst Ratings
BIIB Price Target Range
Latest BIIB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BIIB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2025 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Apr 9, 2025 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $152.00 |
| Apr 4, 2025 | Argus Research | Jasper Hellweg | Hold | Downgrade | $0.00 |
| Feb 18, 2025 | Piper Sandler | Christopher Raymond | Neutral | Reiterates | $135.00 |
| Feb 13, 2025 | Wells Fargo | Mohit Bansal | Equal-Weight | Maintains | $140.00 |
| Feb 13, 2025 | Citigroup | Geoff Meacham | Neutral | Maintains | $145.00 |
| Feb 13, 2025 | Goldman Sachs | Salveen Richter | Buy | Maintains | $245.00 |
| Feb 13, 2025 | BMO Capital | Evan Seigerman | Market Perform | Maintains | $139.00 |
| Feb 13, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $241.00 |
| Feb 13, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $265.00 |
| Feb 13, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $225.00 |
| Feb 13, 2025 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Feb 13, 2025 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $157.00 |
| Feb 13, 2025 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $210.00 |
| Feb 13, 2025 | Scotiabank | George Farmer | Sector Outperform | Maintains | $224.00 |
| Jan 28, 2025 | Citigroup | Geoff Meacham | Neutral | Maintains | $160.00 |
| Jan 10, 2025 | Wells Fargo | Mohit Bansal | Equal-Weight | Maintains | $165.00 |
| Jan 8, 2025 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $220.00 |
| Jan 2, 2025 | Piper Sandler | Christopher Raymond | Neutral | Downgrade | $138.00 |
| Dec 20, 2024 | BMO Capital | Evan Seigerman | Market Perform | Downgrade | $164.00 |
Biogen Inc. (BIIB) Competitors
The following stocks are similar to Biogen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biogen Inc. (BIIB) Financial Data
Biogen Inc. has a market capitalization of $17.36B with a P/E ratio of 10.6x. The company generates $9.68B in trailing twelve-month revenue with a 16.9% profit margin.
Revenue growth is +2.9% quarter-over-quarter, while maintaining an operating margin of +21.5% and return on equity of +10.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Biogen Inc. (BIIB) Business Model
About Biogen Inc.
Develops innovative therapies for neurological diseases.
Biogen generates revenue through the discovery, development, and commercialization of therapies for neurological conditions, focusing on serious medical issues such as multiple sclerosis and Alzheimer's disease. The company invests significantly in research and development, allowing it to create a diverse portfolio of biologics, gene therapies, and small molecule drugs, which are marketed to healthcare providers and patients.
Biogen collaborates with academic institutions and other biotech firms to enhance its research capabilities and expand its product offerings. Based in Cambridge, Massachusetts, the company plays a vital role in the biopharmaceutical industry, contributing to healthcare innovation and improving global health outcomes.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
7,605
CEO
Mr. Christopher A. Viehbacher
Country
United States
IPO Year
1991
Website
www.biogen.comBiogen Inc. (BIIB) Latest News & Analysis
The European Commission has approved Eisai and Biogen's drug for treating mild cognitive impairment in early-stage Alzheimer's disease.
Approval of Eisai and Biogen's Alzheimer's drug could boost their stock prices and increase market competition in the biotech sector, influencing investor sentiment and potential returns.
Lecanemab is approved in the EU for adults with mild cognitive impairment or mild dementia due to Alzheimer's, specifically for ApoE ฮต4 non-carriers or heterozygotes with amyloid pathology.
Lecanemab's approval for early Alzheimer's treatment targets a specific patient demographic, potentially influencing pharmaceutical stocks and market focus on Alzheimerโs therapies.
Biogen and Eisai's Leqembi has received EU approval, becoming the first treatment to slow early Alzheimer's progression in the region.
Leqembi's approval in the EU could drive significant revenue for BIIB and Eisai, impacting stock prices and market sentiment around Alzheimer's treatments.
Biogen (BIIB) experienced significant trading volume recently, but current earnings estimate revisions may hinder its upward momentum in the near term.
Increased trading volume signals heightened interest in Biogen, but downward earnings estimate revisions could lead to potential stock price declines.
Robert F. Kennedy Jr. has been appointed Health Secretary, potentially impacting biotech stocks due to his views on fluoride, vaccines, and beef tallow.
Kennedy's appointment may lead to regulatory shifts impacting biotech stocks, especially in areas like vaccines and health policies, influencing market volatility and investment strategies.
Sage Therapeutics is rated a Strong Buy, trading below cash value. Biogen's $7.22/share buyout offer reflects confidence in Sage's drug pipeline, especially Zuranolone, which shows strong market traction.
Sage Therapeuticsโ Strong Buy rating, undervaluation, and Biogen's buyout offer highlight confidence in its drug pipeline, especially Zuranolone, signaling potential for substantial future growth.
Frequently Asked Questions About BIIB Stock
What is Biogen Inc.'s (BIIB) stock forecast for 2025?
Based on our analysis of 44 Wall Street analysts, Biogen Inc. (BIIB) has a median price target of $185.00. The highest price target is $342.00 and the lowest is $121.00.
Is BIIB stock a good investment in 2025?
According to current analyst ratings, BIIB has 16 Buy ratings, 19 Hold ratings, and 0 Sell ratings. The stock is currently trading at $118.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BIIB stock?
Wall Street analysts predict BIIB stock could reach $185.00 in the next 12 months. This represents a 56.0% increase from the current price of $118.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biogen Inc.'s business model?
Biogen generates revenue through the discovery, development, and commercialization of therapies for neurological conditions, focusing on serious medical issues such as multiple sclerosis and Alzheimer's disease. The company invests significantly in research and development, allowing it to create a diverse portfolio of biologics, gene therapies, and small molecule drugs, which are marketed to healthcare providers and patients.
What is the highest forecasted price for BIIB Biogen Inc.?
The highest price target for BIIB is $342.00 from Morten Herholdt at HSBC, which represents a 188.3% increase from the current price of $118.61.
What is the lowest forecasted price for BIIB Biogen Inc.?
The lowest price target for BIIB is $121.00 from at , which represents a 2.0% increase from the current price of $118.61.
What is the overall BIIB consensus from analysts for Biogen Inc.?
The overall analyst consensus for BIIB is neutral. Out of 44 Wall Street analysts, 16 rate it as Buy, 19 as Hold, and 0 as Sell, with a median price target of $185.00.
How accurate are BIIB stock price projections?
Stock price projections, including those for Biogen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.